Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
The Centers for Disease Control and Prevention (CDC) is urging immediate discontinuation of the use of EzriCare Artificial Tears, an over-the-counter drop for dry eye, after linking various infecti...
Johnson & Johnson reported Jan. 24 that its full year 2022 global surgical vision revenue was $1.31 billion, a 4.6 percent increase (+9.4 percent cc) over $1.25 billion in 2021. Revenue was up 2.0 ...
Japan-based Nidek has issued a field safety notice for all lots of EyeCee One preloaded and EyeCee One Crystal preloaded intraocular lenses (IOLs). The lenses are distributed by Bausch + Lomb. Nide...
The Federal Trade Commission announced Jan. 19 that it had issued an order requiring Ohio-based LCA-Vision, doing business as LasikPlus and Joffe MediCenter, to pay $1.25 million for using deceptiv...
Iantrek, of White Plains, New York, announced Jan. 23 that its novel biostenting procedure reduced intraocular pressure (IOP) nearly 40 percent in a first-in-human trial of 10 patients with open-an...
Sun Pharmaceutical Industries Limited of India received a warning letter from the US FDA dated Dec. 15, 2022, regarding “significant violations” of Current Good Manufacturing Practice (CGMP) regula...
EyePoint Pharmaceuticals announced Jan. 23 that it plans to build a 40 thousand-square-foot manufacturing facility in Northbridge, Massachusetts, to support the global manufacturing of Yutiq and it...
Oxular Limited, of Oxford, UK, announced Jan. 24 that the US FDA had cleared its investigational new drug application for a Phase II trial of suprachoroidal OXU-001 in diabetic macular edema (DME)....
A new study suggests that the root of diabetic retinopathy (DR) appears to lie in the belly—mainly a leaky small intestine that weakens the barrier between gut bacteria and the blood system. Resear...
Longevity Biomedical, of Bothell, Washington, reported Jan. 26 that it has agreed to merge with Denali Capital Acquisition Corp., of the Cayman Islands, a publicly traded special purpose acquisitio...
Three of the 19 ophthalmic acquisitions in 2022 were completed by Alcon; the purchases demonstrate the company’s plan to expand its presence in the ophthalmic pharmaceuti-cals market. In 2022, the ...
Ophthalmic deals in 2022 neared $5.6 billion and included 85 transactions. This compares with $8.5 billion in 2021 and $9.3 billion in 2020. Mergers and acquisitions totaled $1.9 billion; venture c...
Seventy-seven companies revealed their intent to enter the ophthalmic market in 2022, a significant increase over the 57 that announced in 2021. Market Scope categorizes them as “emerging companies...
Bausch + Lomb reported Jan. 17 that it had acquired AcuFocus, maker of the IC-8 Apthera small-aperture intraocular lens (IOL). No financial details on the deal were provided. AcuFocus, of Irvine, C...
The US FDA has approved glaucoma drug Iyuzeh, Laboratoires Théa’s preservative-free formulation of latanoprost 0.005% for open-angle glaucoma or ocular hypertension, US subsidiary Théa Pharma annou...
Privately held Avellino plans to merge with Senior Connect Acquisition Corp., a publicly traded special purpose acquisition company, Senior Connect announced Dec. 5. Scottsdale, Arizona-based Senio...
Retinal gene therapy developer Perceive Biotherapeutics led recent fundraising efforts by ophthalmic companies with $78 million in a Series B round. Funding announced in the past four weeks totaled...
The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in December 2022, according to the agency’s database. Lutronic received clearance for an updated ve...
Market Scope polled surgeons and corporate clients in January 2023 on how they would rank our selections for the top 10 stories of 2022. Their responses appear below. Alcon Makes Big Push into Phar...
Allergan’s blockbuster dry eye drug Restasis finally met its match in 2022. The US FDA approved a generic version of Restasis from Viatris on Feb. 2, 2022, and the generic immediately began eating ...
Biosimilars to established drugs for retinal diseases first became available in 2022 in the major developed markets of Europe, Japan, and the US. Senju Pharmaceuticals rolled out the first ophthalm...
Vuity has been available by prescription in the US for over a year. Multiple direct-to-consumer marketing campaigns were launched following the commercial release. The ads were ubiquitous and certa...
The year closed with European Union political leaders admitting to mistakes in the union’s new medical device regulation (MDR). EU Health Commissioner Stella Kyriakides proposed in December to dela...
Ophthalmologists performed an estimated 1.1 million glaucoma surgeries globally in 2022, with canal-based surgery the fastest-growing product segment, accounting for 228 thousand procedures, or nea...
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.